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29 cases of late extra-hepatic biliary strictures, occurring 6 weeks to 3 years after 
transplantation, were identi¿ ed by MRCP, ERCP or PTC in recipients of deceased 
donor liver transplants between 2002 and 2011 (n=286). Their preoperative sera 
were retrospectively examined for DSA using Luminex single bead assays. Donor 
cells were cross-matched using À ow cytometry. 20 recipients with no evidence of 
biliary pathologies served as control. Acute rejection, hepatitis and demographic 
criteria were considered for matching the control group.
Cumulative class II MFI >500 and/or B-cell cross-match positivity was found to be 
strongly associated with the incidence of late extra-hepatic biliary strictures. Class 
I DSA did not reveal any association. The study group showed cumulative class II 
DSA >500 MFI in 24/29 patients (83%) and B-cell crossmatch positivity in 20/29 
patients (69%). Using both criteria, 26/29 recipients (90%) could have been identi¿ ed 
prior to transplantation for being at risk to develop late biliary strictures. Only 3/20 
recipients (15%) of the control group showed B-cell cross-match positivity. None 
of them had a cumulative class II MFI >200. None of 4/20 controls (20%) with 
cumulative class II MFI >500 showed a positive B-cell cross-match.
This is the ¿ rst evidence indicating that pre-transplant class II DSA and B-cell cross-
match positivity are strongly associated with the risk of developing late extra-hepatic 
biliary strictures following liver transplantation. These data are suggestive for an 
immunological aetiology of non-vascular late biliary strictures.
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Because of the concerns regarding short 	 long-term outcomes after Liver 
Transplantation (LTx) using Donation after Circulatory Death (DCD) compared 
to Donation after Brain Death (DBD) donors, we reviewed the results of DCD-
LTx at our center. Between 2003 and 2010, 30 DCD-LTx and 385 DBD-LTx 
were performed. Demographics, LTx indications, post-LTx peak aspartate amino 
transaminase (AST peak), delayed graft function (DGF) (Olthoff criteria), biliary 
non-anastomotic strictures (NAS), early post-LTx kidney dysfunction (RIFLE 
criteria), re-transplantation rate and patient/graft survival were analyzed. Mean DCD 
donor warm ischemia (stop ventilation to cold perfusion) was 23+/-11’. Median cold 
ischemia was 6h54’ for DCD compared to 8h40’ for DBD-LTx; p=0.0001. Mean 
labMELD was similar for DCD and DBD-LTx (15 vs. 16; p=0.59). Median post-LTx 
AST peak was higher after DCD vs. DBD-LTx (1178 IU/L vs. 651 IU/L; p=0.005). 
DGF rate was similar between DCD and DBD-LTx (25 vs. 24%, p=0.8). The rate 
of NAS was higher after DCD vs. DBD-LTx (33% vs. 12%; p=0.001). Incidence 
of early post-LTx kidney dysfunction was not statistically different after DCD and 
DBD-LTx (37% vs. 23%, p=0.08). On the other hand, regardless the donor type, the 
AST peak - a surrogate of ischemia-reperfusion injury often used as an appropriate 
criterion for DGF evaluation - was associated with a higher rate of early post-LTX 
kidney dysfunction if greater than 2000 (28 vs. 10%, p=0.001) but not with NAS (12 
vs. 15%, p=0.59). Re-transplantation rate within one year post-LTx was 3% after both 
DCD and DBD-LTx. The 1, 3, 	 5-yr patient/graft survival were similar after DCD 
and DBD-LTx (93, 85, 85% vs. 88, 78 	 72%; p=0.3, and 90, 82, 82% vs. 85, 74 	 
68%; p=0.5, respectively). Despite substantial ischemic injury, short	 long-term 
patient/graft survival after DCD-LTx is comparable to DBD-LTx. Careful donor/
recipient selection, rapid donor surgery and short ischemia times are key factors to 
optimize outcome after DCD-LTx. However, strategies to reduce ischemic injury 
and biliary complications remain warranted.
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Introduction
Biliary complications (BC) cause major morbidity and mortality after liver 
transplantation (LT). Literature is replete with articles on early BC (less than 1 year 
post LT); however, little is known about late BC.
Methods
We reviewed retrospectively our prospectively collected data for adult LTs from 
Jan 1997 to Dec 2007. Multiorgan transplants were excluded. Patients with BC 
more than a year after LT (late BC) were compared to patients with BC in the ¿ rst 
year (early BC) and patients who never had BC. Fisher exact tests with post hoc 
Bonferroni test and Kruskal-Wallis analysis with post-hoc Dunn’s test were used for 
comparisons. Univariate and multivariate Cox regression analysis was performed.
Results
1621 LTs were included, 92.4% primary and 7.6% re LTs. 29.3% patients had BC 
with 24.3% early BC (n=384) and 5% late BC (n=82). Late BC included anastomotic 
(53.6%) and nonanastomotic (21.9%) strictures, papillary stenosis (14.6%), stones 
(21.9%), biloma (10.9%) and tumors (1.2%). In the late BC group, 18.2% patients 
had surgical repair, 47.5% patients had resolution of BC, 9.7% had re LT and 32.9% 
patients died in follow-up. Main causes of death in late BC group were Hepatitis 
C (29%) and hepatic artery thrombosis (HAT) (14%). Late BC were associated 
with simultaneous acute cellular rejection (ACR) (21%), chronic rejection (7%) or 
recurrent primary sclerosing cholangitis (3.5%).
On stepwise multivariate Cox regression, use of T-tube (hazard ratio [HR] 2.0, 
95% con¿ dence interval [CI] =1.0-4.0), HAT (HR: 5.3, 95% CI=1.8-15.4), use of 
Cyclosporine (vs. Tacrolimus) (HR: 3.7; 95% CI=2.1-6.6) or steroids (vs. no use) 
at 4 weeks post LT (HR: 2.0; 95% CI=0.9-4.4), female donor gender (HR: 1.6; 95% 
CI=0.94-2.75) and black recipient race (HR: 1.9; 95% CI=0.8, 4.2) were predictors 
for late BC. Patients with early BC had longer ICU stay, higher rates of ACR, HAT 
and infections, higher recipient BMI and donor age, longer warm ischemia time 
and association with re LT.
Between the 3 groups there were no differences in regards to MELD score, cold 
ischemia time, intraoperative hepatic artery À ow, intraoperative blood transfusion, 
donor BMI, B or T cell positive crossmatch and Sirolimus use at 3 months.
Conclusions
While early BC are related to perioperative events, late BC seem to be related 
to disease recurrence or an immunological event. Most late BC do not require 
surgical repair.
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Introduction: We previously demonstrated universal glomerular abnormalities in 
kidney biopsies after orthotopic liver transplantation (OLT). We hypothesize that 
these changes exist prior to OLT and may play an important role in the development 
of renal failure after OLT. We investigated the mechanism of kidney disease in 
patients listed for OLT by immunohistopathologic and genomic analysis of kidney 
biopsies (KB). Methods: Analysis of clinical and pathological data of 21 cirrhotic 
patients (pts) listed for OLT who underwent KB. The Gene expression pro¿ le of 
KB specimens was studied by Affymetric HuGene 1.0 ST expression assay and was 
compared with pre-implantation living donor KBs. Results: Etiology of liver disease: 
hepatitis C (71%), alcoholic hepatitis (24 %) and autoimmune hepatitis (5%). Mean 
MELD, serum creatinine, GFR and proteinuria were 17± 5, 1.9 ±0.7 mg/dl, 42±17 
ml/min and 0.5±0.8 gm/day, respectively. Twelve pts had low complement levels. 
Mesangial proliferation was seen in 20 KBs by light microscopy. Five pts had nodular 
glomerulosclerosis (3 DM), 2 FSGS and 1 MPGN. ImmunoÀ uorescence staining 
showed mesangial, capillary wall or tubular basement-membrane deposition of IgG 
(16), IgM (18), IgA (10), C1Q (11) and C3 (12). Electron microscope in 16 pts showed 
effacement of podocytes (15) and duplication and widening of glomerular basement 
membranes (10). Gene expression pro¿ les by Gene Ontology revealed signi¿ cant 
up-regulation of genes implicated in immune response, including T-cell, leucocyte 
and platelet activation and differentiation. Pathogenesis-based transcripts revealed 
signi¿ cantly increased expression of quantitative cytotoxic T-cell, quantitative 
macrophage, B-cell, natural killer cell, and endothelial cell associated transcripts, 
indicating an ongoing inÀ ammatory immune response.
Conclusion: This study demonstrates the universal presence of glomerular 
abnormalities in KBs of cirrhotic patients. The majority had increases in mesangial 
matrix, podocyte effacement, and widening and duplication of glomerular basement 
membrane, as is also seen in patient’s post-OLT. The increased gene expression 
pro¿ les related to immune activity could indicate immune-mediated mechanisms 
in development of kidney disease in cirrhotic patients.
Abstract# 450
Superior Renal Function Sustained for 24 Months through Early 
Everolimus-Facilitated Reduction of Tacrolimus Versus Standard 
Tacrolimus in De Novo Liver Transplant Recipients: Results of a 
Randomized Trial. P. De Simone,1 O. Detry,1 G. Kintmalm,1 J. Goss,1 
P. McCormick,1 M. Rossi,1 A. Moya,1 P. Lopez,2 G. Junge,2 G. Dong,3 D. 
Joseph,3 C. Duvoux.1 1For the H2304 Study Group, Pisa, Italy; 2Novartis 
Pharma AG, Basel, Switzerland; 3Novartis Pharmaceuticals Corporation, 
New Jersey.
mTOR inhibitors have the potential to reduce calcineurin inhibitor nephrotoxicity 
by minimizing or eliminating the need for their use. The 12 month (M) results of 
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H2304 (NCT00622869) study demonstrated superior renal function with everolimus 
(EVR) plus reduced tacrolimus (rTAC) vs. standard TAC (TAC-C) in de novo liver 
transplant recipients (LTxR). Presented here are 24M renal function results.
For this 24M, multicenter, open-label study 719 de novo LTxR were randomized 
(1:1:1) after a 30-day (±5 days) run-in period with TAC (±mycophenolate mofetil), to 
receive either EVR (C0 3-8 ng/mL) with rTAC (C0 3-5 ng/mL; EVR+rTAC, N=245) 
or EVR (C0 6-10 ng/mL) with TAC withdrawal (TAC-WD; N=231) at M4 or TAC-C 
(C0 6-10 ng/mL; TAC-C, N=243); all patients received corticosteroids. Enrollment 
in TAC-WD arm was stopped early due to higher rejection rates. Main endpoints at 
M24 included composite ef¿ cacy failure rate of treated biopsy proven acute rejection, 
graft loss or death, and evolution of renal function from randomization (RND) to 
M24 measured as eGFR by MDRD4.
At M24, composite ef¿ cacy failure rate in EVR+rTAC arm was comparable to 
TAC-C (10.3% vs. 12.5%, p=0.452). Evolution of renal function from RND to M24 
was superior for EVR+rTAC vs. TAC-C with an adjusted mean difference in eGFR 
change of 6.66 mL/min/1.73m2 (p=0.0018; ITT population). Signi¿ cantly higher 
eGFR with EVR+rTAC was achieved at M2 post-LTx and was maintained until 
M24. On-treatment data showed a decrease in mean eGFR from RND to M24 of 6.6 
mL/min/1.73m2 with EVR+rTAC vs. 13 mL/min/1.73m2 with TAC-C and 2.5 mL/
min/1.73m2 gain with TAC-WD. Urinary protein:creatinine ratio (mg/g) at M24 was 
higher with EVR+rTAC vs. TAC-C (Mean±SD: 194±280 vs. 159±284, p=0.006).
Early introduction of EVR at 1M post-LTx with rTAC showed superior renal 
function sustained for 24M compared to TAC-C, without compromising ef¿ cacy 
in de novo LTxR.
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Background: Preserving renal function in liver transplantation has become paramount 
to improving long-term survival. However, there are limited de¿ nitive studies 
comparing different immunosuppression (IS) regimens in this capacity.
Methods: This was a large-scale longitudinal cohort study of all liver transplants 
at our institution from Jan 2000 - June 2011. Patients were excluded if they were 
<18 years old, multi-organ transplants, or experienced graft loss or death within the 
¿ rst month. Patients were divided into 4 groups based on baseline IS (CNI, IL2-
RA+MMF+CNI, IL2-RA+CNI, CNI+MMF). Renal function was estimated using the 
MDRD equation; change in renal function from baseline was assessed by calculating 
the slope of MDRD. All patients received steroids in conjunction with IS regimens.
Results: 635 transplants occurred during this period; 532 were included in this 
analysis (mean follow-up 4.8 yrs). Baseline demographics and outcome data are in 
Table 1; the only differences at baseline were age, race, MDRD and MELD. Clinical 
outcomes demonstrated that the combination of IL2-RA+CNI +MMF was the only 
regimen that statistically signi¿ cantly improved renal function with lower rates of 
acute rejection (Table 1). This was achieved through CNI minimization (see FK levels 
in Table 1). HCV recurrence was not inÀ uenced by baseline IS regimens. Death and 
graft loss were lowest in quadruple IS regimen. However, Cox Proportional Hazard 
Regression analysis demonstrated that only slope of MDRD inÀ uenced graft loss 
(HR 0.945, p=0.001 [95% CI 0.92-0.98]) in an independent fashion.
Conclusions: The results of this study suggest that quadruple IS regimens can 
safely and effectively preserve renal function and reduce acute rejection rates in 
liver transplant recipients without inÀ uencing HCV recurrence or graft survival.
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Background: The Model for End-Stage Liver Disease (MELD) system prioritizes 
liver allocation to patients in renal failure, increasing the number of simultaneous 
liver-kidney transplants (SLK). Identifying predictors of post-transplant futility 
(90-day or in-hospital mortality) and renal recovery could maximize utilization of 
these scarce resources.
Methods: Analysis of adult LT recipients on pre-transplant RRT from July 2004 
to September 2012 at a single-institution using 33 recipient, donor, and operative 
variables. Multivariate logistic regression was used to identify predictors of futility 
and dialysis dependence at 3-months.
Results: Of 1546 LT recipients, 529 were on RRT (34%). The mean MELD score 
was 38. Compared to patients undergoing LT alone (LTA, n=407), SLK (n=94) 
patients were signi¿ cantly older and more obese, diabetic, and hypertensive, but less 
likely hospitalized, on continuous RRT, ventilator-dependent, or on vasopressors. 
Despite kidney transplantation, 21% of SLK recipients were dialysis-dependent at 
3-months, compared to 43% of LTA recipients (P<0.001). Of all futile LTs (n=94, 
19%), only 4 patients (4%) became dialysis-independent prior to their death. Futile 
LT accounted for 43% and 75% of failures to achieve dialysis independence in LTA 
and SLK, respectively. Multivariate predictors of futility included coagulopathy 
requiring abdominal packing, pre-transplant length of RRT, mechanical ventilation, 
recipient and donor age, and hyperlipidemia. In non-futile patients, multivariate 
predictors of dialysis dependence included non-fulminant etiology, LTA, emergent 
intraoperative RRT, pre-transplant RRT > 7 days, metabolic syndrome, pre-transplant 
stay, and gender (Table).
Futility   Dialysis Dependence at 3 mos
 Odds Ratio P-value  
Odds 
Ratio P-value
Coagulopathy 4.4 <0.01 Non-fulminant etiology 9.6 0.003
Pre-tx RRT > 7 d 3.3 0.001 LTA 8.6 <0.001
Intubation 2.5 0.001 Intraop RRT 4.2 0.04
Recipient age > 55 yrs 2.4 0.002 Pre-tx RRT > 7 d 2.7 0.03
Hyperlipidemia 2.2 0.06 Metabolic Syndrome 2 0.056
Donor age > 45 yrs 2.0 0.01 Pre-transplant LOS > 2 wks 1.9 0.04
   Female 1.6 0.068
Conclusions: We report the largest single-institution experience of LT in patients 
on pre-transplant RRT. We identi¿ ed important predictors of post-LT futility and 
renal recovery that may help to guide the allocation of kidneys in these challenging 
LT recipients.
